lorigerlimab Updated Oct 26
The next catalyst is updated LINNET results at a lower 3 mg/kg Q3W dose, expected in H1 2027, positive data could de-risk the safety profile and support registrational discussions, while further safety issues or weak efficacy would likely impair the asset's value. Meanwhile, watch for partnership/licensing interest in lorigerlimab or the broader pipeline (MGC026), and monitor the stock's elevated ~11% short interest (~10.9 days to cover) which could amplify moves on binary events.
- 25% confirmed ORR and 44% DCR in clear cell gynecologic cancer, a difficult-to-treat tumor type with limited options, is a meaningful early efficacy signal (source: MacroGenics Oct 26, 2026 press release via GlobeNewswire)
- The bispecific PD-1×CTLA-4 design is differentiated from combination checkpoint therapy, potentially offering better tolerability and tumor-localized activity (source: MacroGenics pipeline page)
- Company has $327M cash runway through 2028, providing ample funding to advance lorigerlimab and other pipeline assets without near-term dilution (source: MacroGenics Q2 2026 earnings release)
- 49% Grade ≥3 treatment-related adverse event rate and one Grade 5 (fatal) TRAE in the LINNET study raise significant safety concerns; 24% of patients discontinued due to TRAEs (source: MacroGenics Oct 26, 2026 press release analysis)
- The FDA placed a partial clinical hold on the LINNET study in February 2026 after a patient death, which was only lifted in April 2026, regulatory scrutiny is elevated (source: FDA catalyst data, Feb-Apr 2026)
- MacroGenics already discontinued lorigerlimab in mCRPC after the LORIKEET study failed to support further development, narrowing the addressable market (source: MacroGenics Q3 2025 earnings release)